Research programme: bispecific antibody therapeutics - Merus

Drug Profile

Research programme: bispecific antibody therapeutics - Merus

Alternative Names: MCLA-114; MCLA-122; MCLA-134; MCLA-145; MCLA-158

Latest Information Update: 20 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merus
  • Developer Merus; ProBioGen
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD274 antigen modulators; CD3 antigen modulators; Epidermal growth factor modulators; ERBB-3 receptor modulators; G protein-coupled receptor modulators; PDCD 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Solid tumours
  • Research Multiple myeloma

Most Recent Events

  • 28 Apr 2017 Merus announces intention to submit Clinical Trial Application (CTA) for planned phase I/II trial of MCLA 158 in Colorectal cancer by the end of 2017
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial presented by Merus at 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 15 Nov 2016 Merus received two favourable rulings from the European Patent Office and the Trial Board of the Japanese Patent Office for genetically modified mice and their use to produce common light chain human monoclonal antibodies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top